A Study of Timunox (Thymopentin) in HIV-Infected Patients Receiving Other Anti-HIV Drugs
Phase 2
Completed
- Conditions
- HIV Infections
- Registration Number
- NCT00002332
- Lead Sponsor
- Immunobiology Research Institute
- Brief Summary
To evaluate the mechanism whereby thymopentin appears to retard the progressive immune suppression attributable to HIV infection.
- Detailed Description
Patients are randomized to receive subcutaneous thymopentin or placebo thrice weekly for 4 weeks.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms does thymopentin use to modulate immune suppression in HIV-1 infected patients?
How does thymopentin compare to other immunomodulators like interleukin-2 in HIV treatment regimens?
Which biomarkers correlate with improved lymphoproliferative responses following thymopentin therapy?
What are the potential adverse events associated with thymopentin in combination with nucleoside analogs for HIV?
Are there synergistic effects when thymopentin is combined with antiretroviral drugs like tenofovir or lamivudine?
Trial Locations
- Locations (3)
Dr Marcus Conant
🇺🇸San Francisco, California, United States
Dr Jeffrey Galpin
🇺🇸Tarzana, California, United States
Novum Inc
🇺🇸Pittsburgh, Pennsylvania, United States
Dr Marcus Conant🇺🇸San Francisco, California, United States